AstraZeneca’s COVID-19 vaccine candidate begins late-stage U.S. study
ASTRAZENECA Plc said on Monday it has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of its high profile COVID-19 vaccine candidate. Trial participants will receive either two doses of the experimental vaccine, dubbed AZD1222, four weeks apart, or a placebo, the company said. The trial is being conducted under U.S. government’s Operation Warp […]
